Synthesis, anticancer and FGFR1 inhibitory activity of isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazoline derivatives

Authors

  • O. Yu. Voskoboynik
  • S. A. Starosyla
  • M. V. Protopopo
  • H. P. Volynets
  • S. V. Shyshkina
  • S. M. Yarmoliuk
  • S. I. Kovalenko

DOI:

https://doi.org/10.11603/mcch.2410-681X.2016.v0.i1.6123

Abstract

Presented manuscript describes the synthesis, antitumor and FGFR1 inhibitory activity of novel isoindolo[2,1-a]
[1,2,4]triazino[2,3-c]quinazolines. It was shown that mentioned above substances may be prepared by interaction
of 3-(2-amino-3-R2-5-R3-phenyl)-6-R1-1,2,4-triazin-5(2H)-ones with 2-formylbenzoic and 6-formyl-2,3-dimethoxybenzoic (opianic) acids in acetic acid. It was shown that proper 2-(2-oxo-3-R-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-
6-yl)benzoic acids (or corresponded dimethoxysubstituted analogues) may be considered as intermediates of the
reaction. Spectral properties of synthesized compounds were studied, it was shown that protons in position 8 were
observed at low field as result of the presence of hydrogen bond between hydrogen at position 8 and oxygen at
position 10. The anticancer assay data allowed to identify synthesized compounds as promising antitumor agents.
The FGFR1 inhibitory activity of synthesized compounds was detected and docking study aimed to the evaluation
of mentioned action was conducted.

References

Cytotoxic alkaloids from Houttuynia cordate / S. K. Kim, S. Y. Ryu, J. No [et al.] // Archives of PharmacalResearch. – 2001. – 24 (6). – P. 518–521.

Cytotoxic 5H-Pyrrolo[2,1-a]isoindol-5-one-Containing Alkaloid from a Marine Streptomyces sp. /X. Alvarez-Mico, P. R. Jensen, W. Fenical, C. C. Hughes //Org. Lett. – 2013. – 15 (5). – P. 988–991.

Isoindolo[2,1-a]quinoxaline Derivatives, NovelPotent Antitumor Agents with Dual Inhibition of Tubulin Polymerization and Topoisomerase I / P. Diana, A. Martorana, P. Barraja [et al.] // J. Med. Chem. – 2008. – 51

(8). – P. 2387–2399.

Synthesis, structure, and in vitro anticancer activity of new polycyclic 1,2-diazines / D. Mantu, D. Maftei, D. Iurea [et al.] // Med. Chem. Res. – 2014. – 23 (6). –P. 2909–2915.

Naturally Occurring Human DNA Topoisomerase I Poison / A. Cagir, S. H. Jones, R. Gao [et al.] // J. Am.Chem. Soc. – 2003. – 125 (45). – P. 13628–13629.

Synthesis and biological activity of novel N-cycloalkyl-cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4] triazino[2,3-c]quinazoline-6-yl)thio]acetamides / G. G. Berest, A. Yu. Voskoboynik, S. I. Kovalenko [et al.] // Eur. J.

Med. Chem. – 2011. – 46 (12). – P. 6066–6074. 7. Synthesis of new 6-{[ω-(dialkylamino(heterocyclyl) alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones and evaluation of their anticancer and antimicrobial

activities / G. G. Berest, O. Yu. Voskoboynik, S. I. Kovalenko

[et al.] // Sci. Pharm. – 2012. – 80 (1). – P. 37–65.

Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[ 2,3-c]quinazoline-6-yl)thio]-acetamides: synthesis,cytotoxicity, anticancer activity, compare analysis and docking / S. I. Kovalenko, I. S. Nosulenko, A. Yu. Voskoboynik [et al.] // Med. Chem. Res. – 2013. – 22 (6). –P.2610–2632.

Hydrazinolysis of 3‑R‑[1,2,4]Triazino[2,3-c]quinazolin-2-ones. Synthetic and Theoretical Aspects /T. Yu. Sergeieva, O. Yu. oskoboynik, S. I. Okovytyy [etal.] // J. Phys. Chem. A. – 2014. – 118. – P. 895−1905.

A New One-Step Synthesis of 1,2,4-Triazino[2,3-c] quinazolines / O. V. Karpenko, S. I. Kovalenko, O. O. Chekotylo, S. V. Shishkina // Heterocycles. – 2007. – 71 (3). –P. 619–626.

Zefirov N. S. Stereochemical studies. XXXIV.Quantitative description of ring puckering via torsional angles. The case of six-membered rings / N. S. Zefirov, V. A. Palyulin, E. E. Dashevskaya // J. Phys. Org. Chem. –

– 3. – P. 147–154.

Burgi H.-B. Structure correlation / H.-B. Burgi, J. D. Dunitz. – Second ed. – Weinheim : VCH, 1994.

Boyd M. R. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen / M. R. Boyd, K. D. Paull // Drug Dev. Res. – 1995. – 34. – P. 91–109.

Boyd M. R. The NCI In Vitro Anticancer Drug Discovery Screen; Concept, Implementation and Operation,Cancer Drug Discovery and Development vol. 2 /M. R. Boyd – Humana Press. – 1997.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines / A. Monks, D. Scudiero, P. Skehan [et al.] // J. Nat. CancerInst. – 1991. – 83 (11). – P. 757–766.

Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity / G. M. Morris,R. Huey, W. Lindstrom [et al.] // J. Computational Chemistry. – 2009. – 16. – P. 2785–2791.

Identification of Apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives ofBenzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one / Sergiy A. Starosyla, Galyna P. Volynets, SergiyS. Lukashov [et al.] // Bioorg. Med. Chem. – 2015. – 23. –P. 2489–2497.

Sheldrick G. M. A short history of SHELX /G. M. Sheldrick // Acta. Crystallogr. Sect. A. – 2008. –64. – P. 112–122.

The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site / J. H. Bae, E. D. Lew, S. Yuzawa [et al.] // Cell. –2009. – 138, № 3. – P. 514–524.

Pedretti A. VEGA – An open platform to develop chemo-bio-informatics applications, using plug-in architecture

and script programming / A. Pedretti, L. Villa,G. Vistoli // J.C.A.M.D. – 2004. – 18. – P. 167–173.

http://accelrys.com/

Hastie C. J. Assay of protein kinases using radiolabeled

ATP: a protocol / C. J. Hastie, H. J. McLauchlan,P. Cohen // Nature Protocols. – 2006. – 1, № 2. – P. 968–

Downloads

Published

2016-04-27

How to Cite

Voskoboynik, O. Y., Starosyla, S. A., Protopopo, M. V., Volynets, H. P., Shyshkina, S. V., Yarmoliuk, S. M., & Kovalenko, S. I. (2016). Synthesis, anticancer and FGFR1 inhibitory activity of isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazoline derivatives. Medical and Clinical Chemistry, (1), 5–18. https://doi.org/10.11603/mcch.2410-681X.2016.v0.i1.6123

Issue

Section

ORIGINAL INVESTIGATIONS